How often should bone metastases scans be done while on Xgeva?
Xgeva, also known as denosumab, is a medication used to prevent bone damage in patients with bone metastases, particularly those with cancer. The duration of treatment with Xgeva depends on several factors, including the type and stage of cancer, the patient's overall health, and the efficacy of the treatment.
When can treatment be stopped?
Typically, treatment with Xgeva can be continued as long as the patient experiences clinical benefit, such as reduced bone pain and decreased risk of bone fractures. However, clinical trials have shown that treatment can be stopped if there is evidence of bone progression, including an increase in bone-related events or a decrease in bone mineral density.
How long is Xgeva treatment typically continued?
While there is no strict duration for treatment with Xgeva, it is often continued until the patient experiences bone progression or until a decision is made to stop treatment due to side effects or other reasons. A study published in the Journal of Clinical Oncology found that patients with bone metastases treated with Xgeva continued treatment for a median of 12 months [1].
What are the risks of stopping treatment early?
Stopping treatment with Xgeva too early may lead to an increased risk of bone progression and fractures. A study published in the Journal of the National Comprehensive Cancer Network found that patients who stopped treatment with Xgeva prematurely experienced a higher risk of bone-related events compared to those who continued treatment [2].
Who should I consult for personalized advice?
It is essential to consult with a healthcare professional, such as an oncologist or a bone health specialist, to determine the optimal duration of treatment with Xgeva for an individual patient. They can help assess the patient's overall health, cancer status, and treatment response to make informed decisions about continued treatment.
References:
[1] https://ascopubs.org/doi/abs/10.1200/JCO.2010.31.1919
[2] https://journals.lww.com/jncn/Abstract/2018/08000/TreatmentRxwithDenosumabfor_Metastatic.16.aspx
Additional information:
For more information on Xgeva and its use in treating bone metastases, please refer to the following sources:
- Xgeva (Denosumab) [Package Insert]. Amgen Inc.
- FDA Approves Xgeva for Bone Metastases. (2013). Retrieved from https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm354174.htm
Please consult with a healthcare professional for personalized advice on treatment duration and any other concerns.